Welcome to our dedicated page for Celularity news (Ticker: CELUW), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (Nasdaq: CELU; warrants: CELUW) is frequently in the news as a regenerative and aging-related cellular medicine company focused on placenta-derived biomaterials and cell therapies. Its news flow covers developments across wound care, longevity-focused cell therapy, ophthalmic biologics, and corporate and capital markets activity. Readers following CELUW-related headlines can use this page to see how Celularity’s scientific, clinical, commercial, and financing updates intersect with the value of its listed warrants.
Company press releases highlight clinical milestones, such as publication of Phase 2 trial results for PDA-002, a placenta-derived mesenchymal stromal-like cell therapy evaluated in complex diabetic foot ulcers with peripheral artery disease. Other news items describe real-world evidence for Biovance human amniotic membrane allograft products in chronic wound healing, as well as the impact of Medicare coverage and payment policies on skin substitute products used in wound care.
Celularity also reports on strategic partnerships that extend its platform into new settings. Examples include a collaboration with Fountain Life to supply stem cell therapy products for use under a Florida statute governing stem cell therapies in orthopedics, wound care, and pain management, and an exclusive sublicense and manufacturing role for DefEYE, Inc. in ophthalmic biologics, including Biovance, Biovance 3L, Interfyl, and CentaFlex.
In addition, Celularity’s news includes financing transactions, balance sheet restructuring, and Nasdaq listing compliance updates, all of which can influence perceptions of risk and opportunity around CELU common stock and CELUW warrants. Investors and observers can use this news feed to monitor clinical data releases, reimbursement and regulatory developments, strategic alliances, and capital structure changes that the company discloses over time.
Celularity Inc. (Nasdaq: CELU) has received a delisting notice from Nasdaq due to delayed filings of its Q1 and Q2 2024 Forms 10-Q. The company plans to appeal the decision and request a hearing to present its compliance plan. CELU stock continues trading on Nasdaq Capital Market under symbols 'CELU' and 'CELUW'.
The company has filed its 2023 annual report and Q1 2024 report, with Q2 2024 report expected in the coming weeks. CEO Robert J. Hariri attributes the delays to financial challenges and resource constraints, not accounting issues. He expresses confidence in the company's future, citing the recent Rebound™ product acquisition as a boost to cash position and operational stability.
Celularity Inc. (Nasdaq: CELU) has expanded its commercial portfolio of placental-derived advanced biomaterial products by acquiring Rebound™, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. This acquisition is expected to contribute significantly to Celularity's fourth quarter 2024 sales and help fulfill the company's projected full-year 2024 biomaterial sales.
Celularity's Chairman, CEO, and founder, Robert J. Hariri, M.D., Ph.D., highlighted that the company's biomaterial product sales in the first half of 2024 exceeded $24 million, surpassing their full-year sales in 2023. The addition of Rebound complements Celularity's existing portfolio and enhances its ability to address a broader patient population in wound care and soft tissue repair.
This strategic acquisition aligns with Celularity's vision of expanding its offerings and reinforces its leadership in the field of placental-derived biomaterials. The company continues to differentiate itself in the regenerative medicine market by leveraging the unique properties of placental tissues to provide advanced, natural solutions designed to improve healing outcomes.
Celularity (Nasdaq: CELU), a regenerative and cellular medicine company, announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference. The event will take place at the Lotte New York Palace Hotel from September 9-11, 2024. Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and founder of Celularity, is scheduled to present on Monday, September 9, 2024, at 12:30 p.m. ET.
In addition to the presentation, Celularity will engage in one-on-one investor meetings during the conference. Interested parties can contact H.C. Wainwright representatives or KCSA Strategic Communications to schedule meetings. A replay of the presentation will be available on Celularity's website for at least 90 days following the event.
Celularity Inc. (Nasdaq: CELU) has appointed Richard J. Berman to its Board of Directors. Berman brings over 40 years of experience in venture capital, senior management, and mergers and acquisitions. He has served as a director and/or officer of more than a dozen public and private companies, with six reaching over $1 billion in market value. Berman's background includes working at Goldman Sachs and as Senior Vice President at Bankers Trust Company, where he established the M&A Leveraged Buyout Departments. He has advised on over $4 billion in M&A transactions, completing over 300 deals. Celularity's CEO, Robert J. Hariri, welcomed Berman's unique depth of experience in guiding public companies and executing growth plans.
Celularity Inc. (Nasdaq: CELU), a regenerative and cellular medicine company, received a notification from Nasdaq on August 22, 2024, regarding non-compliance with listing requirements due to delayed filing of its Q2 2024 Form 10-Q. The company also remains delinquent in filing its Q1 2024 Form 10-Q. This notice does not immediately affect the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market.
Celularity must submit a compliance plan to Nasdaq by September 6, 2024, and if accepted, has until October 14, 2024, to implement it. The company intends to submit a plan and is working to file both Q1 and Q2 2024 Form 10-Qs. However, there is no guarantee that Nasdaq will accept the plan or that Celularity will regain compliance within the given timeframe.
Celularity Inc. (Nasdaq: CELU) reported full year 2023 combined net sales of $22.8 million, a 26.7% increase over 2022. The company expects first half 2024 combined net sales of $25.8 to $27.8 million, representing a 290% growth over the first half of 2023. For Q1 2024, Celularity anticipates combined net sales of $14.8 million, surpassing previous guidance. The company is on track to file a 510(k) premarket submission for its Celularity Tendon Wrap in the second half of 2025. Celularity's product portfolio includes four commercial-stage products and three development pipeline candidates, focusing on placental-derived allogeneic allografts and connective tissue matrices for soft tissue repair and reconstructive procedures.
Celularity has presented promising in vivo data at the ASCO Annual Meeting showing the potential of its T-cell therapy platform, PT-CD16VS, in targeting multiple hematological and solid tumors. The platform leverages genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells and can be combined with various monoclonal antibodies. Previous data at AACR demonstrated efficacy against HER2-positive cancers, and the recent findings extend this potential to a broader range of cancers. The company is also expanding its pipeline to tackle aging-related healthcare issues such as cellular senescence.
Celularity (Nasdaq: CELU), a regenerative medicine company, received a Nasdaq notice on May 21, 2024, for not filing its Q1 2024 Form 10-Q and 2023 Form 10-K on time. This puts Celularity in non-compliance with Nasdaq's listing requirements, but it doesn't affect the current trading of its stock and warrants. Celularity must submit a compliance plan by June 17, 2024, and has until October 14, 2024, to regain compliance if the plan is accepted. The company is working to complete its filings but cannot guarantee Nasdaq will accept the plan or that it will meet future requirements.
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to those derived from adult peripheral blood mononuclear cells (PBMCs). Key findings include longer telomeres and attenuated cytokine responses without loss of cytotoxicity. These advantages may lead to more effective and scalable CAR-T therapies. Dr. Robert Hariri, CEO of Celularity, emphasized the potential of their platform to deliver improved and durable allogeneic CAR-T products.
Summary not available.